Related Experiment Video
Updated: Jun 7, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development
Cancan Lyu1, Prasanna Kuma Vaddi1, Said Elshafae1
1Departments of Neuroscience and Pharmacology, University of Iowa, Iowa City, USA.
Abstract:
The dysregulated PI3K/AKT pathway is pivotal in the onset and progression of various cancers, including prostate cancer. However, targeting this pathway directly poses challenges due to compensatory upregulation of alternative oncogenic pathways. This study focuses on the novel regulatory activity of the Receptor for Activated Protein Kinase (RACK1), a scaffolding/adaptor protein, in governing the PI3K/AKT pathway within prostate cancer. Through a genetic mouse model, our research unveils RACK1's pivotal role in orchestrating AKT activation and the genesis of prostate cancer. RACK1 deficiency hampers AKT activation, effectively impeding prostate tumor formation induced by PTEN and p53 deficiency. Mechanistically, RACK1 facilitates AKT membrane translocation and fosters its interaction with mTORC2, thereby promoting AKT activation and subsequent tumor cell proliferation and tumor formation. Notably, inhibiting AKT activation via RACK1 deficiency does not trigger feedback upregulation of HER3 and androgen receptor (AR) expression and activation, distinguishing it from direct PI3K or AKT targeting. These findings position RACK1 as a critical regulator of the PI3K/AKT pathway and a promising target for curtailing prostate cancer development arising from pathway aberrations.
Insights
Receptor for Activated Protein Kinase 1 (RACK1) is crucial for prostate cancer development by activating the PI3K/AKT pathway. Targeting RACK1 may offer a new strategy for prostate cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The PI3K/AKT pathway is frequently dysregulated in cancers, including prostate cancer.
- Directly targeting the PI3K/AKT pathway can lead to compensatory activation of other oncogenic pathways.
- Receptor for Activated Protein Kinase 1 (RACK1) is a scaffolding protein with a potential role in cancer signaling.
Purpose of the Study:
- To investigate the role of RACK1 in regulating the PI3K/AKT pathway in prostate cancer.
- To determine if RACK1 is a viable therapeutic target for prostate cancer.
Main Methods:
- Utilized a genetic mouse model of prostate cancer with PTEN and p53 deficiency.
- Assessed the impact of RACK1 deficiency on AKT activation, membrane translocation, and mTORC2 interaction.
- Evaluated downstream effects on tumor cell proliferation and tumor formation.
- Monitored HER3 and androgen receptor (AR) expression and activation in response to RACK1 inhibition.
Main Results:
- RACK1 deficiency significantly impaired AKT activation and impeded prostate tumor formation in the PTEN/p53 deficient mouse model.
- RACK1 was found to facilitate AKT membrane translocation and interaction with mTORC2, promoting AKT activation.
- Inhibition of AKT activation via RACK1 deficiency did not lead to feedback upregulation of HER3 or AR.
- RACK1 plays a critical role in orchestrating AKT activation and driving prostate cancer development.
Conclusions:
- RACK1 is a key regulator of the PI3K/AKT pathway in prostate cancer.
- Targeting RACK1 presents a promising therapeutic strategy for prostate cancer, potentially avoiding resistance mechanisms associated with direct PI3K/AKT inhibitors.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades

